ARQT Q2 2025 Earnings — Arcutis Biotherapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ARQTArcutis Biotherapeutics, Inc.

$3B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$82M+164.1% YoY

Gross Profit

$74M90.8% margin

Operating Income

-$15M-17.9% margin

Net Income

-$16M-19.5% margin

EPS (Diluted)

$-0.13

QoQ Revenue Growth

+23.8%

Cash Flow

Operating Cash Flow

$324,000

Free Cash Flow

$246,000

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$352M

Total Liabilities

$213M

Stockholders' Equity

$139M

Cash & Equivalents

$73M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$82M	$31M	+164.1%
Gross Profit	$74M	$27M	+170.2%
Operating Income	-$15M	-$50M	+70.8%
Net Income	-$16M	-$52M	+69.6%